NEW YORK, Aug. 8 – Exelixis on Wednesday reported a second-quarter net loss of $23.7 million, or 30 cents per share, compared with $11.0 million, or 16 cents per share, during the comparable period last year despite posting a 54 percent surge in total revenue.

Wall Street had predicted a net loss of 31 cents per share, according to a poll of six brokers conducted by First Call/Thomson Financial.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.